Hi 1nat1mat,
“Our results offer evidence of a therapeutic mechanism of action and a clear direction for further NASH studies. The growing literature implicating LPS in many diseases offers the potential for a much wider scope for LPS antagonism as a treatment modality. With IMM-124E being the world’s First-In Class Oral LPS Antagonist we are very confident, that when combined with its exceptional safety, there are substantial opportunities ahead across a broad range of diseases”.
World's First-In Class Oral LPS Antagonist.
That is the big kicker for me.
Add to My Watchlist
What is My Watchlist?
